FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesActing Decisively
Members
Environmental Sustainability & the Supply of Medicines for Use in Clinical Trials
Topic: Supply Chain
White Paper
Free
GDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
